Liquidia Corp.: We Have Exposure To The Upside Now
If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Arquitos Capital Management Q4 2024 Commentary
Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full ...
United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...